ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca will provide funding for more than 80 Ph.D.s and eight clinical lectureships at England’s University of Cambridge over the next five years. The firm will fund a minimum of nine four-year scholarships annually across the departments of chemistry, biochemistry, and pharmacology. It will also have the option of enrolling two of its employees annually as Ph.D. students. MedImmune, AstraZeneca’s biologics arm, and the university have also established a joint program supporting up to six Ph.D. students annually. AstraZeneca is due to open its headquarters and an R&D center in Cambridge next year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter